Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $11.80 USD
Change Today -0.12 / -1.01%
Volume 1.7M
MACK On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

merrimack pharmaceuticals in (MACK) Snapshot

Open
$11.88
Previous Close
$11.92
Day High
$12.15
Day Low
$11.72
52 Week High
04/27/15 - $13.84
52 Week Low
07/28/14 - $5.53
Market Cap
1.3B
Average Volume 10 Days
1.1M
EPS TTM
$-0.85
Shares Outstanding
110.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MERRIMACK PHARMACEUTICALS IN (MACK)

merrimack pharmaceuticals in (MACK) Related Bloomberg News

View More Bloomberg News

merrimack pharmaceuticals in (MACK) Related Businessweek News

No Related Businessweek News Found

merrimack pharmaceuticals in (MACK) Details

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Its therapeutic oncology candidates in clinical development include MM-398, a nanotherapeutic encapsulation of the chemotherapy drug irinotecan, which is has completed Phase III clinical trials for the treatment of patients with metastatic pancreatic cancer whose cancer had progressed on treatment with the chemotherapy drug gemcitabine; in a Phase I clinical trial as a monotherapy in patients with glioma and in combination with cyclophosphamide in patients with pediatric solid tumors; and in a Phase 1 translational clinical trial designed to identify predictive biomarkers associated with MM-398. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trial for the treatment of patients with ErbB2 (HER2)-positive, locally advanced or metastatic breast cancer; MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer, as well as ovarian, breast, and non-small cell lung cancers; and MM-111 that is in a Phase II clinical trial for the treatment of patients with advanced gastric, esophageal, and gastroesophageal junction cancers. In addition, its therapeutic oncology candidates consist of MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has collaboration and license agreements with Baxter International Inc., Baxter Healthcare Corporation, Baxter Healthcare SA, Actavis, Sanofi, PharmaEngine, Inc., Dyax Corp., Adimab LLC, and University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

306 Employees
Last Reported Date: 02/27/15
Founded in 1993

merrimack pharmaceuticals in (MACK) Top Compensated Officers

Chief Executive Officer, President, Executive...
Total Annual Compensation: $527.3K
Chief Financial Officer and Treasurer
Total Annual Compensation: $293.9K
Senior Vice President of Corporate Operations
Total Annual Compensation: $351.7K
Head of Commercial and President of Merrimack...
Total Annual Compensation: $305.7K
Senior Vice President of Development
Total Annual Compensation: $273.2K
Compensation as of Fiscal Year 2014.

merrimack pharmaceuticals in (MACK) Key Developments

Merrimack Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Merrimack Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported collaboration revenues of USD 14,842,000 against USD 13,034,000 a year ago. Loss from operations was USD 30,026,000 against USD 23,514,000 a year ago. Net loss attributable to the company was USD 34,759,000 against USD 27,585,000 a year ago. Basic and diluted net loss per share available to stockholders was USD 0.32 against USD 0.27 a year ago. Net cash used in operating activities was USD 35,079,000 against USD 31,387,000 a year ago.

Merrimack Pharmaceuticals, Inc. Announces Initiation of Phase 2 Front-Line Clinical Trial of MM-141

Merrimack Pharmaceuticals, Inc. announced the initiation of a randomized, double-blinded, placebo-controlled Phase 2 clinical trial of MM-141, a bispecific antibody targeting IGF-1R and ErbB3, in combination with nab-paclitaxel and gemcitabine, versus nab-paclitaxel and gemcitabine alone in patients with newly-diagnosed metastatic pancreatic cancer who have high serum levels of free IGF-1. As part of this trial, 146 front-line metastatic pancreatic cancer patients with high serum levels of free IGF-1 will be randomized (1:1) to receive either MM-141 plus nab-paclitaxel/gemcitabine or nab-paclitaxel/gemcitabine alone. Eligible patients for the trial must have received no prior radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of metastatic disease. The primary endpoint of the trial is progression free survival (PFS). Secondary endpoints include overall survival, objective response rate, safety and tolerability. Merrimack plans to conduct the trial at sites in the United States, Canada and Europe.

Merrimack Pharmaceuticals, Inc. Presents at Credit Suisse 2015 Antibody Day, May-06-2015 10:55 AM

Merrimack Pharmaceuticals, Inc. Presents at Credit Suisse 2015 Antibody Day, May-06-2015 10:55 AM. Venue: Credit Suisse, One Madison Avenue at 24th Street, 12th Floor, New York, New York, United States. Speakers: Gavin MacBeath, Co-Founder & Head of Translational Research, Geoffrey Grande, IR.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MACK:US $11.80 USD -0.12

MACK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MACK.
View Industry Companies
 

Industry Analysis

MACK

Industry Average

Valuation MACK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERRIMACK PHARMACEUTICALS IN, please visit www.merrimackpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.